China-based IMEIK Technology Development Co.,Ltd (SHE: 300896) announced the establishment of Imeik International Limited, a joint venture with Aisheng Shourui (HK) Limited. The primary objective of this joint venture is to acquire 85% stakes in South Korea-headquartered REGEN Biotech, Inc. for USD190 million. As part of this transaction, IMEIK will contribute USD133 million.
About REGEN Biotech
Founded in 2000, REGEN Biotech is a leading medical aesthetics product company in South Korea. The company boasts two approved skin filler products, AestheFill and PowerFil. This acquisition is poised to enhance IMEIK’s presence in the global medical aesthetics market.
Strategic Implications
The acquisition of a significant stake in REGEN Biotech represents a strategic move for IMEIK to expand its portfolio in the medical aesthetics sector. By leveraging REGEN Biotech’s established products and market presence, IMEIK aims to accelerate its growth and innovation in this competitive industry.-Fineline Info & Tech
Leave a Reply